Carregant...
Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
Tumor-associated macrophage (TAM) significantly contributes to cancer progression. Human cancer is enhanced by PPARγ loss-of-function mutations, but inhibited by PPARγ agonists such as TZD diabetes drugs including rosiglitazone. However, it remains enigmatic whether and how macrophage contributes to...
Guardat en:
| Publicat a: | eLife |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
eLife Sciences Publications, Ltd
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5047746/ https://ncbi.nlm.nih.gov/pubmed/27692066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.18501 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|